← Eichor
Study identifier: NCT04961593 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PK/PD of Caspofungin in Children Severe Infection

Condition: Pharmacokinetics · Infection, Fungal  ·  Sponsor: Children's Hospital of Fudan University

PhaseN/A
Planned participants60
Who can joinAll sexes, 3 Months to 18 Years
Healthy volunteersNo

About this study

Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. There is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. The study aim to investigate PK/PD of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ECMO treatment, or sepsis.

This description comes directly from the study's public registry record.

Talk to the study team

Yixue Wang, doctor  ·  8613524669352  ·  yixuewang08@aliyun.com

Always discuss trial participation with your own doctor first.

Locations (2)

Children's Hospital of Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting
Children's Hospital of Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04961593